Drugs / CB-5339
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04372641 | Jun 2020 → Jul 2021 | metastatic malignant neoplasm, non-Hodgkin lymphoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT04402541 | Jun 2020 → Jul 2023 | acute myeloid leukemia, myelodysplastic syndrome | Cleave Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-06 | CASI pharmaceuticals, Inc. | Regulatory CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA issuerdirect.com ↗
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-20 | CASI pharmaceuticals, Inc. | CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 issuerdirect.com ↗ |
| 2023-01-06 | CASI pharmaceuticals, Inc. | CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA issuerdirect.com ↗ |
| 2021-03-08 | CASI pharmaceuticals, Inc. | Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region issuerdirect.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-5339 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04402541 ↗ |
| Action | Inhibit | “p97 inhibitor CB-5339 tosylate” NCT04372641 ↗ |
| Route | Oral | “administered orally” NCT04372641 ↗ |